Site Editor

Jennifer R. Brown, MD, PhD


5-Year Follow-up of ELEVATE-TN: Obinutuzumab-Based Regimens for CLL

By: Victoria Kuhr, BA
Posted: Friday, July 22, 2022

Jeff Porter Sharman, MD, of US Oncology Network, Woodlands, Texas, and colleagues reported on the 5-year follow-up data from the ELEVATE-TN trial. They found the efficacy and safety of the combination of acalabrutinib and obinutuzumab as well as acalabrutinib monotherapy were maintained in patients with treatment-naive chronic lymphocytic leukemia (CLL). In fact overall survival was significantly longer with the acalabrutinib-based therapy compared with obinutuzumab plus chlorambucil. These findings were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 7539).

The 5-year follow-up study randomly assigned patients to receive acalabrutinib plus obinutuzumab, acalabrutinib monotherapy, or obinutuzumab plus chlorambucil. Patients whose disease progressed on obinutuzumab/chlorambucil treatment could cross over to acalabrutinib monotherapy.

The study included 535 patients: 179 received acalabrutinib/obinutuzumab, 179 received acalabrutinib monotherapy, and 177 received obinutuzumab/chlorambucil. The median age of patients was 70.

The median progression-free survival was not reached for acalabrutinib/obinutuzumab or acalabrutinib at 58.2 months of follow-up. The estimated 60-month progression-free survival rates were 84% for acalabrutinib/obinutuzumab, 72% for acalabrutinib monotherapy, and 21% for obinutuzumab/chlorambucil. The median overall survival was not reached in any treatment arm. However, the overall survival rate was significantly longer with acalabrutinib/obinutuzumab than with obinutuzumab/chlorambucil (P = .0474). The estimated 60-month overall survival rates were 90% with acalabrutinib/obinutuzumab, 84% with acalabrutinib monotherapy, and 82% with obinutuzumab/chlorambucil. The overall response rate was significantly higher with acalabrutinib/obinutuzumab (P <.0001) and acalabrutinib monotherapy (P =.0499) than with obinutuzumab/chlorambucil. The complete response/complete response with incomplete hematologic recovery rates were higher with acalabrutinib/obinutuzumab (29%/3%) versus obinutuzumab/chlorambucil (13%/1%).

Treatment was ongoing in 65% of patients given acalabrutinib/obinutuzumab and 60% of patients given acalabrutinib. The most common reasons for treatment discontinuation were adverse events (17% [acalabrutinib/obinutuzumab], 16% [acalabrutinib monotherapy], 14% [obinutuzumab/chlorambucil]) and progressive disease (6%, 10%, 2%, respectively). Crossover from obinutuzumab/chlorambucil to acalabrutinib treatment occurred in 72 patients (41%). Of the 72 patients, 25% discontinued treatment with acalabrutinib.

Disclosures: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.